Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts

Transcription

1 Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2 1. Report Overview 1.1 Overview of the World Market for Those Medicines Anti-cancer drugs form the most lucrative sector in pharmaceuticals, accounting for over 10% of the global market. Kinase inhibitors are novel targeted therapeutics designed improve patient survival by preventing tumour growth selectively as opposed to indiscriminate cell-death from classical chemotherapy. In 2014, global sales of small molecule kinase inhibitors will generate $18.49bn for manufacturers. Sales growth will exceed that of the wider cancer-treating drug market, owing to expanded use of targeted inhibitors for increasingly stratified patient populations. Growth will also be stimulated by the launch and uptake of breakthrough therapies such as a marketed product, Imbruvica (Ibrutinib), and candidate drugs Palbociclib, Idelalisib and ABT-199. As with other medicines for cancer, the US, EU, and Japan form the dominant markets for revenues. However over the next ten years exceptional growth is forecast in the BRIC countries, owing to insurance and healthcare reforms and increased affluence. Over the course of our forecast period, , the first-generation of kinase inhibitor drugs will lose patent protection, and competition from low-cost generics will restrict sustained expansion across a variety of the submarkets covered in this study. Rising demand for personalised cancer treatments has been a core feature of the oncology drugs market in recent years. Inhibition of protein kinases has been at the heart of this shift, owing to an increasing body of scientific evidence for their crucial role in cancer biology. Market growth will continue to be underpinned by product innovation. On this front, we have seen a number of first-in-class molecules coming to the market in recent years, including inhibitors of: anaplastic lymphoma kinase (ALK), Bruton s tyrosine kinase (BTK), and Janus kinase (JAK) inhibitors. This trend of innovative launches is set to continue over the next five years, as cyclin-dependent kinase and phosphatidylinositol-3-kinase inhibitors reach the market. Market dynamics are also driven by demographics that will lead to an increase in incidence and prevalence of many cancers. The global population is ageing, with the population over the age of 65 years set to exceed 800 million by This is problem in developed regions, especially Japan and Page 23

3 Europe, but is increasingly an issue in large emerging markets such as Brazil and China. Jonathan Weymer; pharmaceutical and healthcare industry analyst, visiongain, 2014 Figure 1.1 Forecast Global Population Over the Age of 65 Years Old (millions), Annual Growth Rate (%), World 65+ Population (m) Annual Growth Rate (%) 4.0 Global 65+ Population (m) Annual Growth Rate (%) Year 0.0 Source: visiongain 2014; UN Population Study Page 24

4 Figure 1.2 Anti-Cancer Kinase Inhibitor Market Segmentation, 2014 Anti-Cancer Kinase Inhibitor Market Bcr-Abl Inhibitors Angiogenesis Inhibitors EGFR Inhibitors mtor Inhibitors Other Kinase Inhibitors BRAF and MEK Inhibitors Generics and Others Pipeline Drugs Source: visiongain Why You Should Read This Report This report investigates commercial trends and revenues of the anti-cancer kinase inhibitors market from 2014 to 2024, also with historical data. In particular that study discusses sales potentials of: eight submarkets (Figure 1.2), 25 marketed anti-cancer kinase inhibitors and 11 of the leading pipeline candidate molecules. This new analysis focuses on commercial prospects of individual products, along with the kinase inhibitor market overall. That investigation also discusses forces driving and restraining revenue sales expansion at overall world market, national, submarket and product level. The study also examines opportunities and challenges that for that industry and market, as well as economic forces affecting its companies. In particular the work gives revenue forecasts to 2024 for that market and its top products, by brand and category. In particular, this new study will: Help your research, analyses, decisions, presentations, proposals and business plans Highlight commercial opportunities submarkets, products and countries with highest sales potentials, also giving you revenue forecasts to 2024 Benefit your knowledge of that industry, helping your authority and influence Provide intelligence on competitors and their activities, especially products, deals and R&D Page 25

5 Keep you up to date with commercial developments events shaping that business Help you evaluate companies in the kinase inhibitor field developers, producers and sellers Explain trends to watch strengths, weaknesses, opportunities and threats Help your organisation to succeed through getting insight on that industry and market, especially technological and commercial prospects from How This Report Delivers This report delivers added value by providing this analysis: Global anti-cancer kinase market forecasting and discussions covering the period 2013 to 2024 Product level analysis of clinical trial data, safety and efficacy, patent protection status, and sales forecasts to 2024 Product submarket, regional, and national market forecasts and discussions from 2014 to 2024 Revenue forecasts to 2024 for leading products and expected new drugs in the kinase inhibitor industry Transcript of a visiongain interview with an authority in the industry Analysis of strengths and weaknesses of the anti-cancer kinase inhibitor market, together with the opportunities available and the threats to be overcome (SWOT forces) Porter s five forces analysis of the market for anti-cancer kinase inhibitors Analysis of technological developments, economic, political, and social (STEP) factors affecting the kinase inhibitor market from Benefit your work now through our new study, gaining this industry and market analysis: Revenue to 2024 for the world kinase inhibitors market discover the sales potential of that cancer treatments industry Revenues to 2024 for 7 submarkets investigate medical categories at world level, finding the most promising product groups Revenues to 2024 for 35 drugs and 6 leading companies find sales predictions for top medicines and their producers, seeing how they can compete and succeed Forecasts to 2024 for 11 national markets in the Americas, Europe and Asia find the best countries for commercial expansion Page 26

6 Activities of established, rising and emerging companies hear about firms products, capabilities, advances and outlooks, also with industry opinion Discussions of R&D investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities Analysis of what stimulates and restrains that kinase inhibitors market assess challenges and strengths, helping you compete and gain advantages. 1.4 Main Questions Answered by This Analysis How is the anti-cancer kinase inhibitor market evolving and what are its prospects from 2014? What forces stimulate and restrain that market? What are the market sales figures for kinase inhibitors used to treat cancer? Tables 1.1 and 1.2 and Figures 1.1 and 1.2 show excerpts of analyses explored in more detail in later chapters. What shares of the market do classes of kinase inhibitors occupy? How will revenues of kinase inhibitor segments grow over the forecast period, 2014 to 2024? How will individual product sales develop to 2024? Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials? Which submarkets will be the main drivers of the overall world market from 2014 to 2024? How will social, technological, economic and political forces influence regional markets and world-level submarkets? How will market shares of top countries change by 2024 with their revenues - and which regions will lead the market in 2024? Who are leading companies and what are their prospects over the forecast period? Visiongain predicts that anti-cancer drugs market will achieve strong revenue growth over the next ten years. This report examines in detail that market by overall world revenues, leading country, product, and kinase inhibitor class, helping you identify promising sales areas and business opportunities. Page 27

7 Table 1.1 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) Total Market ($bn) Annual Growth (%) US ($bn) Annual Growth (%) EU ($bn) 5.84 Annual Growth (%) Japan ($bn) Annual Growth (%) China ($bn) Annual Growth (%) Brazil ($bn) Annual Growth (%) 21.0 Russia ($bn) Annual Growth (%) India ($bn) Annual Growth (%) 17.0 Others ($bn) 2.35 Annual Growth (%) Source: visiongain Page 28

8 Table 1.2 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) Total Market ($bn) Annual Growth (%) US ($bn) Annual Growth (%) -2.0 EU ($bn) Annual Growth (%) 5.0 Japan ($bn) 3.50 Annual Growth (%) 1.0 China ($bn) 1.45 Annual Growth (%) 28.0 Brazil ($bn) 1.02 Annual Growth (%) India ($bn) 0.24 Annual Growth (%) Russia ($bn) 0.75 Annual Growth (%) 11.0 Other ($bn) Annual Growth (%) 7.7 Source: visiongain Page 29

9 1.5 Who is This Study For? Kinase Inhibitors for Treating Cancer: Industry Forecasts helps readers understand that industry and its prospects. That analysis helps companies wishing to expand into different sectors or explore a new region for expansion of operations. This report also explores market drivers, restraints, forecasts, technologies, investments, risks, and leading companies, to help you formulate business strategy. This study suits pharma executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and directors, among other professionals. Also governments, agencies and other industry bodies will find value in this investigation. 1.6 Methods of Research and Analysis Visiongain s reports are compiled using a mix of primary and secondary information to produce an overall industry outlooks. That secondary and primary research is blended to produce a cohesive analytical report. The skill of the analyst is in sifting through vast amounts of available information to produce a cohesive industry outlook that is well argued and which, owing to its breadth of sources, is comprehensive. That is where visiongain s expertise adds value. Visiongain believes those research methods, reinforced with views and predictions of its analysts and interviewees, produces an accurate and objective market analysis to help your work. Primary Research To give you the best product possible, visiongain s analysts interview leading companies and other authorities. Interviews cover a broad range of topics, from detailed technical product issues to insight into forces driving that industry and market at the local and macroeconomic level. Those interviews are transcribed and published in full in our reports. Secondary Research Secondary research is performed by analysing sales data and regulatory filings from a multitude of sources including company annual and quarterly reports, SEC filings, sales reports, company web sites, news reports, online and in-house databases, industry journals, clinical trial reports, conference abstracts, analyst earnings, call transcripts, business news, and other statistical publications. By using an array of sources, and not relying upon one source of data, visiongain assesses industries and markets, striving to help your research, analyses and decisions. Page 30

10 Market Evaluation and Forecasting Methods Market evaluation uses the bottom-up approach that involves analysing sales data from a multitude of sources such as annual reports, online and in-house databases, industry journals, and other statistical publications, and by consulting other authorities, especially people in that industry. Regional market share data and company market share data are also derived from a similar baseup data analysis. The secondary data sources are matched with primary research insight from company interviews and blended with the SWOT analysis to develop forecasts. The experience of analysts allows them to consider historical trends and assess future growth rates on a year-by-year basis, forming a vision of commercial potentials over a 10 year period, predicting that industry s revenue prospects. That is the main purpose of a visiongain report. Table 1.3 Foreign Currency Exchange Rates Utilised: 2013 Average Exchange Rate to $US Euro (EUR) Swiss Franc (CHF) Chinese Yuan (CNY) British Pound (GBP) Indian Rupee (INR) Japanese Yen (JPY) South Korean Won (KRW) Mexican Peso (MN) Brazilian Real (BRL) Russian Rouble (RUB) Turkish Lira (TRY) Canadian Dollar (CAD) Australian Dollar (AUS) Danish Krone (DKK) Source: Oanda.com 1.7 Frequently Asked Questions (FAQ) How are market forecasts produced? Please refer to our methods, as outlined in this chapter (especially section 1.6). Why do you not show the sources for your data? In the vast majority of cases, the market data revealed is our own visiongain data compiled from a very broad combination of our own in house databases, our own market evaluation, company Page 31

11 annual reports, other secondary data and our primary research. In cases where data is being quoted directly, the source is credited to the organisation or source of data. Why does the report not provide market forecasts for all national markets? Why are some countries not included? The aim of the report is to identify the leading national markets so the reader can assess where the greatest business potential will be. Furthermore, in some cases there is insufficient data or the data available does not meet our high quality threshold, hence we decide to not include it. Does the report provide year-by-year market forecasts for the leading national markets? Yes, the report quantifies the leading national markets in USD each year with annual growth rates. Does the report just contain market forecasts or do they also contain supporting written analysis explaining the reasons behind the forecast? Yes, the supporting text explains the forecast and provides context to justify our forecasting. Why are all of the regions or countries not segmented by application or technology? We aim to provide clients with the best possible information available that we believe can be relied upon. However, in some cases, that extra detail is not possible or the data available is not reliable enough to meet our quality threshold, hence we decide to omit it. Why does the report not mention every single company in the sector? The report is primarily a market forecast report to assist investment decisions and therefore focuses upon the market evaluation, revenue forecasts and demand-side factors. As such, our work is not intended to be an exhaustive business directory. However we profile a selection of companies operating in field the report covers, where we highlight leading organisations. How is the report delivered? PDF format is the favoured option, as it is instant, secure and easily used across multiple platforms, PCs, laptops, tablets and even smart phones, allowing you to view content while in the office or on the move. 1.8 Some Associated Reports Visiongain publishes other healthcare reports that may interest you, including these titles. Next -Generation Biologics: R&D, Industry and Market Industry-and-Market Page 32

12 Biosimilars and Follow-On Biologics: World Industry and Market Prospects Biologics-World-Market Next-Generation Antibody Therapies: World Industry and Market World-Industry-and-Market Orphan Drugs for Cancer: R&D and Market Market World Biological Drugs Market Small-Molecule Targeted Cancer Therapies: World Market Therapies-World-Market About Visiongain Visiongain is one of the fastest growing business intelligence providers, helping you keep abreast of changes taking place in your industry. Based in London, UK, visiongain publishes market analysis produced by in-house analysts, many of whom are educated to masters and PhD level and are experts in their field. Visiongain has achieved a reputation for examining difficult, cutting edge topics that other companies have yet to realise are significant game changers. Stay ahead with visiongain s knowledge base. Visiongain has established itself as the first port-of-call for the business professional who needs independent, high quality, original business intelligence to depend upon. Technology is moving rapidly, so it is important that you understand the Page 33

13 opportunities that lie ahead with changes in technologies, materials, regulations and the evolving economic landscape. Visiongain produces market analysis reports on many industries, including these fields: Automotive Aviation Construction Defence Energy: Oil & Gas Food & Drink IT Maritime Medical Devices Metals Packaging Pharmaceuticals Plastics Renewable Energy Telecoms Utilities. By reading a visiongain report, commissioning its bespoke research, following its twitter feeds or subscribing to a visiongain newsletter, you will be better informed and equipped to face challenges and harness business opportunities that lie ahead. Stay abreast, then, of issues affecting your industry. You will see the growth prospects for your market and how its subsectors can develop over a 10 year forecast period. Visiongain's reports and bespoke research are comprehensive market-based products with analyses and opinions to benefit your work, aiming to save you time and aid your business strategy, helping you harness opportunities to maximise profits and secure your company s future. Page 34